Read our Recent Headlines


June 14 Biotech Update

It is Friday again, so be on the lookout for those rumors or late day runners. A slow start to the morning in terms of price action but we are.

June 13 Biotech Update

I am back but honestly we are entering the summer quite period with little news to drive the sector higher or lower. We did get a break from the macro,.

June 6 Biotech Update

Nothing has really changed. Oddly the sector is really underperforming the market today at the start, which is not good but at least we are seeing an end to the.

June 4 Biotech Update

Are we bouncing or starting a new trend higher? Both are plausible explanations for the recent move as the selling has been pretty consistent and so a dead cat bounce.

June 3 Biotech Update

Guess what? The macro continues to dominate but it might actually work for us this week. If Mexico can work out a deal with the US, then the market is.

May 31 Biotech Update

Macro, Macro, Macro. No this is not a complete repeat of yesterday but it sure is looking like one. It would be really nice to have at least some time.

May 30 Biotech Update

Macro, Macro, Macro. I am sort of getting sick of it but at least it is working to the upside today (at least for now). Hopefully with ASCO coming this.

Introduction


Overview

Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.


The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate. Subscribe to Chimera Research Group and proceed with confidence.

Get Started!